Navigation Links
Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
Date:8/6/2008

Milestone achievement triggers $15 million payment from collaborator

GlaxoSmithKline

CAMBRIDGE, Mass., Aug. 6 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company engaged in the discovery and development of novel therapies for immune-mediated diseases, today announced the initiation of a pivotal Phase 3 clinical trial that is evaluating otelixizumab in autoimmune new onset type 1 diabetes. As a result of the initiation of patient dosing in DEFEND (Durable Response Therapy Evaluation For Early or New Onset Type 1 Diabetes), Tolerx will receive a $15 million milestone payment from GlaxoSmithKline.

DEFEND is a randomized, placebo controlled Phase 3 trial designed to enroll approximately 240 adult patients, age 18 to 35, with newly diagnosed autoimmune type 1 diabetes. DEFEND is being conducted at multiple centers in North America and Europe. The trial will evaluate whether a single course of otelixizumab, administered not more than 90 days after the initial diagnosis of autoimmune type 1 diabetes, will reduce the amount of administered insulin required to control blood glucose levels by inhibiting the destruction of beta cells. The primary endpoint will be a measurement of C-peptide, a surrogate measure of beta cell function. Maintenance of beta cell function has been associated with improved glycemic control (HbA1c levels), fewer hypoglycemic events, and a reduction in long-term disease complications in established type 1 diabetics in the Diabetes Control and Complications Trial (DCCT).

"We are excited to have dosed the first patient in DEFEND and look forward to continued patient enrollment in this Phase 3 clinical trial. The initiation of DEFEND represents the culmination of a methodical, dose-ranging development plan, including the successful outcome from an end-of-Phase 2 meeting at FDA. We believe otelixizumab has the potential to provide an important new treatment option for patients with newly dia
'/>"/>

SOURCE Tolerx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
2. Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
3. Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
4. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
7. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
8. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
9. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
10. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
11. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... , Nov. 24, 2014  Relmada Therapeutics, Inc. ... the treatment of chronic pain, announced today that ... present at the LD MICRO "MAIN Event" Micro-Cap Growth ... be held at the Luxe Sunset Bel Air Hotel, ... Los Angeles, California . The ...
(Date:11/24/2014)... Calif. , Nov. 24, 2014  Rigel Pharmaceuticals, Inc. ... Gower is retiring from the board of directors and ... Raul Rodriguez , most recently serving as the company,s ... chief executive officer and join the board of directors.  ... since 2005, will become chairman. Mr. Gower is expected to ...
(Date:11/23/2014)... 2014  Aurobindo Pharma USA ... 300 mg 100-count bottles to the consumer level. The ... capsules. Empty capsules could result in missed ... could range from no effect, short term reduction in ... period seizures) that could be life-threatening. Aurobindo Pharma ...
Breaking Medicine Technology:Relmada Therapeutics To Present At LD MICRO Conference 2Rigel Announces Executive Management Changes 2Rigel Announces Executive Management Changes 3Aurobindo Pharma USA, Inc. Issues Voluntary Nationwide Recall of Northstar Label Gabapentin Capsules, USP 300 mg Due to Complaints of Empty Capsules 2
(Date:11/24/2014)... 24, 2014 Volpara Solutions announced ... at the 100th Annual Meeting of the Radiology ... 2014 (RSNA Booth 1752 – South Hall). Volpara ... and the rest of its innovative suite of ... which enable personalized measurements of volumetric density, patient-specific ...
(Date:11/24/2014)... SweetDressy.com, a well-known dress supplier and leader in the ... Dresses. All these fresh items are offered at affordable ... special offer is valid until Dec. 20, 2014. Click ... working well in the fashion industry for years. They ... dresses may be the best products for many ladies ...
(Date:11/24/2014)... SafeHandles™ announced that they will be featured in ... airing via Discovery Channel. Dates and show times TBA. ... replaceable, and affordable germ protective device. This segment will ... adhesives to promote hand hygiene in high traffic and ... is the desire to make a positive impact in ...
(Date:11/23/2014)... The clinical trial report, "Aspergillosis ... on the Aspergillosis clinical trial scenario. This report ... clinical trials on Aspergillosis. It includes an overview ... as per the site of trial conduction across ... of disease clinical trials by their phase, trial ...
(Date:11/23/2014)... Vancouver, BC (PRWEB) November 23, 2014 Pro ... recently announced that it will now be providing an 8 ... number of hot water tank installations went up due to ... Care to assure its customers of the premium service that ... be offering 8 year warranty on John Wood and Bradford ...
Breaking Medicine News(10 mins):Health News:Volpara Solutions to Launch VolparaAnalytics 1.2 at RSNA 2Health News:Volpara Solutions to Launch VolparaAnalytics 1.2 at RSNA 3Health News:SweetDressy.com Unveiled A New Selection Of Evening Dresses 2Health News:New Episode of Innovations TV Series to Feature SafeHandles™ 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 3Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 4Health News:Pro Ace Care Now Gives 8 Year Guarantee on Selected Vancouver Hot Water Tanks 2
... (HealthDay News) -- Emergency dispatchers should advise bystanders to ... the standard protocol of chest compressions and mouth-to-mouth ventilation, ... the results of other recent reports that have compared ... be the key to successful CPR, according to this ...
... second time this year, a postdoctoral fellow in UT ... highly competitive career-development grant from the National Institutes of ... to receive the K99/R00 Pathway to Independence Award. The ... comes from the National Institute on Aging, which usually ...
... Julia Vantine HealthDay Reporter , THURSDAY, ... depression that uses intense magnetic pulses to stimulate the ... periods, appears to work over the longer term when ... address the question of whether the benefit of TMS ...
... G. Daniel (FACHE, FAAMA, Diplomate of Healthcare Administration), ... (LSDC) in Lakeland, Fla., has been named the ... presented by the Association for Professionals in Infection ... award at a Washington news conference kicking off ...
... , THURSDAY, Oct. 14 (HealthDay News) -- Yoga that includes ... fibromyalgia, a small study finds. Twenty-five women diagnosed with ... yoga class that met once a week for eight weeks. ... put on a waiting list and told to continue their ...
... long hours or just about anyone burning the candle at both ... Have a candy bar. Goof off, tune out for a bit ... better. After all, you,re physically exhausted. But a new study ... is well all in your head. In a ...
Cached Medicine News:Health News:More Evidence That Compression-Only CPR Works Best 2Health News:Grant to fund aging research 2Health News:Magnet Therapy an Option for Tough-to-Treat Depression 2Health News:Magnet Therapy an Option for Tough-to-Treat Depression 3Health News:APIC honors Florida ambulatory surgery center executive 2Health News:Yoga May Combat Fibromyalgia Symptoms 2Health News:Yoga May Combat Fibromyalgia Symptoms 3Health News:Yoga May Combat Fibromyalgia Symptoms 4Health News:Need a study break to refresh? Maybe not, say Stanford researchers 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: